Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol
Arvind Chopra1 
Preeti Chavan-Gautam2 
Girish Tillu2 
Manjit Saluja1 
Swapnil Borse2 
Sanjeev Sarmukaddam1 
Susmita Chaudhuri3 
BCS Rao4 
Babita Yadav4 
Narayanam Srikanth4 
Bhushan Patwardhan2*- 1Center for Rheumatic Diseases, Pune, India
- 2Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India
- 3Translational Health Science and Technology Institute (THSTI), Faridabad, India
- 4Central Council for Research in Ayurvedic Science, New Delhi, India
by Chopra, A., Chavan-Gautam, P., Tillu, G., Saluja, M., Borse, S., Sarmukaddam, S., Chaudhuri, S., Rao, B. C. S., Yadav, B., Srikanth, N., and Patwardhan, B. (2022). Front. Med. 9:761655. doi: 10.3389/fmed.2022.761655
In the original article, there was an error in the sentence “One tablet of Ashwagandha or placebo will be administered twice daily (on empty stomach in the morning and after dinner) with water.”
The correction has been made to the Eligibility section, “Trial Intervention” sub section and the corrected sentence appears below:
“One tablet of Ashwagandha or placebo will be administered daily (on empty stomach in the morning) with water.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: COVID-19, immunogenicity, Withania somnifera, vaccine, Ayurveda, Ashwagandha, immunoadjuvant
Citation: Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao BCS, Yadav B, Srikanth N and Patwardhan B (2022) Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol. Front. Med. 9:888928. doi: 10.3389/fmed.2022.888928
Received: 03 March 2022; Accepted: 09 March 2022;
Published: 29 March 2022.
Edited and reviewed by: Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France
Copyright © 2022 Chopra, Chavan-Gautam, Tillu, Saluja, Borse, Sarmukaddam, Chaudhuri, Rao, Yadav, Srikanth and Patwardhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bhushan Patwardhan, bpatwardhan@gmail.com